Total (Immuno)Therapy: Version 2.0.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2024-11-26 DOI:10.1158/2643-3230.BCD-24-0236

Susan Bal, Luciano J Costa

引用次数: 0

Abstract

Among patients with poly-refractory myeloma, autologous chimeric antigen receptor T-cell therapy offers exceptional promise. With the availability of bispecific antibodies, a total immunotherapeutic strategy in combination with chimeric antigen receptor T-cell therapy is now feasible. See related article by Fandrei, p. XX.

查看原文本刊更多论文

全面（免疫）疗法》：2.0 版。

在多发性难治性骨髓瘤患者中，自体嵌合抗原受体T细胞疗法大有可为。随着双特异性抗体的出现，结合嵌合抗原受体 T 细胞疗法的整体免疫治疗策略现已变得可行。见 Fandrei 的相关文章，第 XX 页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.